中止
医学
皮肤病科
皮疹
蕈样真菌病
内科学
耐火材料(行星科学)
淋巴瘤
生物
天体生物学
作者
Amy Musiek,Sean Whittaker,Steven M. Horowitz,Martine Bagot,Auris Huen,David C. Fisher,Paul Haun,Maarten H. Vermeer,Takahiro Ito,Karen Dwyer,Fiona Herr,Youn H. Kim
标识
DOI:10.1016/s0959-8049(21)00712-7
摘要
Background: MAVORIC, a phase 3, randomized trial, evaluated mogamulizumab (Moga) safety and efficacy vs vorinostat (Vori) in patients (pts) with relapsed/refractory mycosis fungoides (MF) or Sézary syndrome (SS) (NCT01728805). Moga-associated rash (MAR) was the second most common TEAE in the Moga treatment arm and most common TEAE leading to treatment discontinuation (7% discontinuation rate, 13/184). Grade 1–2 and 3 drug rashes (DR) occurred in 20% (36/184) and 4% (8/184) of Moga pts, respectively.
科研通智能强力驱动
Strongly Powered by AbleSci AI